CTOs on the Move

Medicrea

www.medicrea.com

 
The MEDICREA Group specializes in the design, manufacture, and distribution of innovative proprietary technologies devoted exclusively to spinal surgery. Operating in a $10 billion market, MEDICREA is a small to medium-sized business with 140 employees, including 40 at its MEDICREA USA Corp. subsidiary based in New York City. The Company enjoys an excellent and ever-improving reputation, and develops unique scientific partnerships with some of the most visionary and creative spine surgeons in France, the UK, and the USA. The products developed and patented by MEDICREA provide neurosurgeons and orthopedic surgeons specializing in the spine with new and less-invasive surgical solutions that ...
  • Number of Employees: 5K-10K
  • Annual Revenue: $1-10 Million
  • www.medicrea.com
  • 50 Greene Street 5th Floor
    New York, NY USA 10013
  • Phone: 646.490.2360

Executives

Name Title Contact Details

Similar Companies

ACell

ACell, Inc. is a leading regenerative medicine company focused on the development, manufacturing, and commercialization of unique proprietary extracellular matrix (ECM) products to facilitate the repair and remodeling of damaged tissues. ACell is committed to becoming and remaining an innovative leader in regenerative medical technology, offering superior healing options for doctors and patients. ACell is a privately held company and operates manufacturing facilities in Columbia, MD and Lafayette, IN.

Accumed Systems

Accumed Systems is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Daymark Recovery Service

Daymark Recovery Services provides an array of out patient counseling and psychiatric services for the treatment of a mental illness, substance abuse problem or developmental disability. Services are tailored to individual needs and delivered using

Orametrix

Orametrix is a Richardson, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ValenTx

ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.